© Copyright 2001-2023 Erowid Center. DrugsData is a project of
Erowid Center. All rights reserved.
By using this site you agree not to publish its images, data, results, or analysis of its results without written permission from Erowid Center.
Permission is required before using data from DrugsData in any of these ways, including importing it into public or shared databases, software, or systems.
This policy has been in place since 2001 in order to require cooperation and credit by researchers and app authors.
Your javascript is turned off.
To remove this message, turn on javascript and accept the Terms of Use.
Unidentified Substance #1: 5 parts [identified as FXE, later corrected]
Unidentified Substance #2: 1 part
All samples analyzed by the DrugsData lab prior to early 2023 that were reported as containing Fluorexetamine have been reexamined in comparison to this new standard. They have all been retroactively revised; they all contain 2-Fluoro-2-oxo PCE, including this sample. To date, no samples tested by DrugsData have contained 3-Fluoro-2-oxo PCE.
Apr 18 2022: The more abundant unidentified substance has been identified as Fluorexetamine. A certified reference standard for Fluorexetamine was ordered, and, this identification was confirmed.
Jan 04 2022: Sample re-analyzed, alpha-D2PV confirmed in this sample by comparison to reference standard for alpha-D2PV.
We need the help of outside expert analytical chemists and drug geeks to determine what substance matches the mass spectrum (MS) fingerprint. The lab's GC/MS graphs can be viewed by clicking on the thumbnails on this page.
Please use our contact form and include the DrugsData ID (11706) or this URL along with any communications.